Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Economic Burden of Parkinson’s Disease : A Multinational, Real-World, Cost-of-Illness Study

Chaudhuri, K. Ray ; Azulay, Jean Philippe ; Odin, Per LU orcid ; Lindvall, Susanna ; Domingos, Josefa ; Alobaidi, Ali ; Kandukuri, Prasanna L. ; Chaudhari, Vivek S. ; Parra, Juan Carlos and Yamazaki, Toru , et al. (2024) In Drugs - Real World Outcomes
Abstract

Background: Parkinson’s disease is now one of the fastest-growing neurodegenerative disorders in the developed world, with an increasing prevalence and associated socioeconomic costs. Progression of the disease leads to a gradual deterioration in patients’ quality of life, despite optimal treatment, and both medical and societal needs increase, often with the assistance of paid and/or unpaid caregivers. Objective: We aimed to quantify the incremental economic burden of Parkinson’s disease by disease severity in a real-world setting across differing geographic regions. Methods: Demographics, clinical characteristics, health status, patient quality of life, caregiver burden, and healthcare resource utilization data were drawn from the... (More)

Background: Parkinson’s disease is now one of the fastest-growing neurodegenerative disorders in the developed world, with an increasing prevalence and associated socioeconomic costs. Progression of the disease leads to a gradual deterioration in patients’ quality of life, despite optimal treatment, and both medical and societal needs increase, often with the assistance of paid and/or unpaid caregivers. Objective: We aimed to quantify the incremental economic burden of Parkinson’s disease by disease severity in a real-world setting across differing geographic regions. Methods: Demographics, clinical characteristics, health status, patient quality of life, caregiver burden, and healthcare resource utilization data were drawn from the Adelphi Parkinson’s Disease Specific Program™, conducted in the USA, five European countries, and Japan. Results: A total of 563 neurologists provided data for 5299 individuals with Parkinson’s disease; 61% were male, with a mean age of 64 years. Approximately 15% of individuals were deemed to have advanced disease, with significantly more comorbidities, and a poorer quality of life, than those with non-advanced disease. Overall, the mean annual healthcare resource utilization increased significantly with advancing disease, and resulted in a three-fold difference in the USA and Europe. The main drivers behind the high economic burden included hospitalizations, prescription medications, and indirect costs. Conclusions: People with Parkinson’s disease, and their caregivers, incur a higher economic burden as their disease progresses. Future interventions that can control symptoms or slow disease progression could reduce the burden on people with Parkinson’s disease and their caregivers, whilst also substantially impacting societal costs.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
Drugs - Real World Outcomes
publisher
Adis International
external identifiers
  • pmid:38193999
  • scopus:85181904450
ISSN
2199-1154
DOI
10.1007/s40801-023-00410-1
language
English
LU publication?
yes
id
74353d89-6c1a-474d-ae5e-41e8efbd4646
date added to LUP
2024-02-09 13:26:11
date last changed
2024-04-25 16:21:36
@article{74353d89-6c1a-474d-ae5e-41e8efbd4646,
  abstract     = {{<p>Background: Parkinson’s disease is now one of the fastest-growing neurodegenerative disorders in the developed world, with an increasing prevalence and associated socioeconomic costs. Progression of the disease leads to a gradual deterioration in patients’ quality of life, despite optimal treatment, and both medical and societal needs increase, often with the assistance of paid and/or unpaid caregivers. Objective: We aimed to quantify the incremental economic burden of Parkinson’s disease by disease severity in a real-world setting across differing geographic regions. Methods: Demographics, clinical characteristics, health status, patient quality of life, caregiver burden, and healthcare resource utilization data were drawn from the Adelphi Parkinson’s Disease Specific Program™, conducted in the USA, five European countries, and Japan. Results: A total of 563 neurologists provided data for 5299 individuals with Parkinson’s disease; 61% were male, with a mean age of 64 years. Approximately 15% of individuals were deemed to have advanced disease, with significantly more comorbidities, and a poorer quality of life, than those with non-advanced disease. Overall, the mean annual healthcare resource utilization increased significantly with advancing disease, and resulted in a three-fold difference in the USA and Europe. The main drivers behind the high economic burden included hospitalizations, prescription medications, and indirect costs. Conclusions: People with Parkinson’s disease, and their caregivers, incur a higher economic burden as their disease progresses. Future interventions that can control symptoms or slow disease progression could reduce the burden on people with Parkinson’s disease and their caregivers, whilst also substantially impacting societal costs.</p>}},
  author       = {{Chaudhuri, K. Ray and Azulay, Jean Philippe and Odin, Per and Lindvall, Susanna and Domingos, Josefa and Alobaidi, Ali and Kandukuri, Prasanna L. and Chaudhari, Vivek S. and Parra, Juan Carlos and Yamazaki, Toru and Oddsdottir, Julia and Wright, Jack and Martinez-Martin, Pablo}},
  issn         = {{2199-1154}},
  language     = {{eng}},
  publisher    = {{Adis International}},
  series       = {{Drugs - Real World Outcomes}},
  title        = {{Economic Burden of Parkinson’s Disease : A Multinational, Real-World, Cost-of-Illness Study}},
  url          = {{http://dx.doi.org/10.1007/s40801-023-00410-1}},
  doi          = {{10.1007/s40801-023-00410-1}},
  year         = {{2024}},
}